US3167475A - Anti-anaphylactic compositions - Google Patents

Anti-anaphylactic compositions Download PDF

Info

Publication number
US3167475A
US3167475A US76504A US7650460A US3167475A US 3167475 A US3167475 A US 3167475A US 76504 A US76504 A US 76504A US 7650460 A US7650460 A US 7650460A US 3167475 A US3167475 A US 3167475A
Authority
US
United States
Prior art keywords
anaphylactic
compositions
alkanolamines
ethanolamine
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US76504A
Other languages
English (en)
Inventor
Gottfried Siegfried
Baxendale Lily
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorex Laboratories Ltd
Original Assignee
Biorex Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Laboratories Ltd filed Critical Biorex Laboratories Ltd
Application granted granted Critical
Publication of US3167475A publication Critical patent/US3167475A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines

Definitions

  • alkanolamines and compounds derived therefrom possess valuable anti-anaphylactic activity when administered experimentally to guinea pigs.
  • These alkanolamine compounds can be administered in simple vehicles, such as distilled water, or in more elaborate vehicles, such as tablet bases.
  • These alkanolamine compounds produce a protective action which can be observed as an increase in the time in which sensitized animals can tolerate an antigen without undergoing anaphylactic shock.
  • compositions should be of considerable value in the treatment of allergic conditions, such as asthma, urticaria or conditions in which some allergic mechanism represents a contributory factor.
  • the low molecular weight alkanolamines which are used according to the present invention may be represented by the general formula:
  • R R and R which may be same or different, are hydrogen atoms or methyl or ethyl radicals; and the esters, salts, amides and quaternary ammonium salts thereof.
  • Examples of compounds which may be added to the alkanolamines are ipecacuanha and cocillana (i.e., expectorants), codeine and pholcodine (i.e., anti-tussives), mepyramine maleate and phenindamine tartrate (i.e., anti-histiminics), adrenaline and ephedrine (i.e., antiasthmatics), prednisone and triamcinolone (i.e., corticosteroids and corticosteroid-like compounds), tetracycline and chloramphenicol (i.e., antibiotics), creosote and cetrimide B.P.
  • ipecacuanha and cocillana i.e., expectorants
  • codeine and pholcodine i.e., anti-tussives
  • mepyramine maleate and phenindamine tartrate i.e., anti-histiminics
  • bactericides i.e., bactericides
  • domiphen bromide and benzalkonium chloride i.e., bacteriostatics
  • aspirin cortisone
  • xanthoglabrol i.e., glycyrrhetinic acid and derivatives thereof (i.e., anti-inflammatory agents)
  • xanthines and ephedrine i.e., bronchodilators
  • the compositions according to the present invention may be made up in the form of inhalations, aerosols, tablets, injections, onematas, suppositories, ointments, lotions and suspensions by admixice ture with an appropriate solid or liquid pharmaceutical carrier or diluent.
  • alkanolamines coming within the scope of the above general formula are ethanolamine, N-methylethanolamine, 'N,N-dimethyl-ethanolamine, choline, N- ethyl-ethanolamine, N,N-diethyl-ethanolamine, N,N,N- triethyl-N-ethylol ammonium salts, N-methyl-Z-aminopropanol, N,N-dimethyl-2-amino-propanol, 2-aminopropanol, N,N,N-trimethyl-N-(Z-propylol) ammonium salts, phoshatidyl-ethanolamine and ethanolamine phosphatase.
  • alkanolamines according to the present invention synergism exists between the alkanolamines according to the present invention and blood pressure-reducing drugs, such as pentaerythrityl tetranitrate, diuretic drugs, such as acetazolarnide and chloroth'iazide, and anti-coagulant drugs, such as phenindione.
  • blood pressure-reducing drugs such as pentaerythrityl tetranitrate
  • diuretic drugs such as acetazolarnide and chloroth'iazide
  • anti-coagulant drugs such as phenindione.
  • Such compositions may be used, for example, in the treatment of arteriosclerosis and coronary thromboses.
  • Fiat tabella. Injection 200 mg. diphenylhydramine hydrochloride 1000 mg. ethyanolamine succinate 900 mg. sodium chloride 100 ml. distilled water 900 mg. domiphen bromide
  • the resultant solution is sterilized by heating for 30 minutes at C. 1 cc. of the sterilized solution is injected as required
  • Enema 200 mg. ethanolamine maleate '100 mg. mepyramine maleate mg. sodium chloride 10 mg. prednisolone phosphate ml. distilled water 0.1% w./w. cetrimide (5)
  • Suppository 200 mg. diphenylhydramine hydrochloride 1000 mg. ethyanolamine succinate 900 mg. sodium chloride 100 ml. distilled water 900 mg. domiphen bromide
  • Enema 200 mg. ethanolamine maleate '100 mg. mepyramine maleate mg. sodium chloride 10 mg. prednisolone phosphate ml.
  • a tablet consisting essentially of 1 part by weight of 2 [-(2 dimethylamino ethyl) (p methoxybenzyl) amino1-pyridine maleate and 2 parts by Weight of choline hydrochloride.
  • Anti-anaphylactic composition of matter consisting essentially of 2-5 parts by Weight of a member selected from the group consisting of alkanolamines of the formula and the pharmaceutically acceptable quaternary ammonium salts and pharmaceutically acceptable bases thereof, in which R; is a member selected from the group consisting of hydrogen, methyl and ethyl, R is a member selected from the group consisting of hydrogen, methyl and ethyl, and R is a member selected from the group consisting of hydrogen, methyl and ethyl and one part by Weight of 2-[(2-dimethy1aminoethyl) (p-methoxybenzyl)-amino]-pyridine maleate, in admixture with a pharmaceutical carrier.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US76504A 1959-12-31 1960-12-19 Anti-anaphylactic compositions Expired - Lifetime US3167475A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB44460/59A GB915813A (en) 1959-12-31 1959-12-31 Anti-anaphylactic compositions comprising alkanolamines and derivatives thereof

Publications (1)

Publication Number Publication Date
US3167475A true US3167475A (en) 1965-01-26

Family

ID=10433387

Family Applications (1)

Application Number Title Priority Date Filing Date
US76504A Expired - Lifetime US3167475A (en) 1959-12-31 1960-12-19 Anti-anaphylactic compositions

Country Status (3)

Country Link
US (1) US3167475A (en, 2012)
FR (1) FR874M (en, 2012)
GB (1) GB915813A (en, 2012)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2081516A1 (en, 2012) * 1970-02-16 1971-12-03 Bristol Myers Co
US4140798A (en) * 1976-11-24 1979-02-20 Kewanee Industries, Inc. Method of inhibiting microorganisms
US4683243A (en) * 1984-02-08 1987-07-28 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4755532A (en) * 1984-02-08 1988-07-05 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4906625A (en) * 1984-02-08 1990-03-06 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and metyhods of using same
AT390878B (de) * 1984-02-08 1990-07-10 Richardson Vicks Inc Verfahren zur herstellung einer pharmazeutischen zubereitung unter einsatz eines analgetischen und antiinflammatorischen nichtsteroiden wirkstoffes
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
WO2020021483A1 (en) * 2018-07-27 2020-01-30 Grzegorz Kalbarczyk Arkona Laboratorium Farmakologii Composition for the treatment of oral cavity inflammations

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2469923A1 (fr) * 1979-11-26 1981-05-29 Ile De France Nouveau medicament a base d'aspirine et d'heptaminol
US6013273A (en) * 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2081516A1 (en, 2012) * 1970-02-16 1971-12-03 Bristol Myers Co
US4140798A (en) * 1976-11-24 1979-02-20 Kewanee Industries, Inc. Method of inhibiting microorganisms
US4683243A (en) * 1984-02-08 1987-07-28 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4755532A (en) * 1984-02-08 1988-07-05 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4906625A (en) * 1984-02-08 1990-03-06 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and metyhods of using same
AT390878B (de) * 1984-02-08 1990-07-10 Richardson Vicks Inc Verfahren zur herstellung einer pharmazeutischen zubereitung unter einsatz eines analgetischen und antiinflammatorischen nichtsteroiden wirkstoffes
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
WO2020021483A1 (en) * 2018-07-27 2020-01-30 Grzegorz Kalbarczyk Arkona Laboratorium Farmakologii Composition for the treatment of oral cavity inflammations

Also Published As

Publication number Publication date
FR874M (en, 2012) 1961-10-16
GB915813A (en) 1963-01-16

Similar Documents

Publication Publication Date Title
US3167475A (en) Anti-anaphylactic compositions
EP2877444B1 (en) Inhibitors of histone deacetylase
US7326690B2 (en) Modulation of cell fates and activities by phthalazinediones
US4775529A (en) Steroid lotion
JPH01104023A (ja) 眼用保存製剤およびその製法
JPS6187623A (ja) ジアゼピン含有医薬組成物
JPH04364124A (ja) 灌注によるショック状態の処置用医薬組成物
KR20170095896A (ko) 페놀성 trpv1 작용제의 프로드러그
CN116440110B (zh) 托品酸及其衍生物在制备免疫与炎症相关疾病治疗药物中的医药用途
PL190023B1 (pl) Zastosowanie mieszaniny diolu i alfa-hydroksykwasu do wytwarzani leku do leczenia hiperkeratozowychchorób skóry
CN101835470A (zh) 包含缩氨基脲和缩氨基硫脲的药物组合物和治疗炎症、疼痛和发热病症和防止炎症体征及症状的方法
Scherbel et al. IV. Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthritis
Calnan Use and abuse of topical steroids
Yang et al. Pemphigoid diseases in patients with end-stage kidney diseases: Pathogenesis and treatment
AU2020202338A1 (en) Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
Hirschberg et al. Laboratory evaluation of a new nitrogen mustard, 2-[di-(2-chloroethyl) aminomethyl] benzimidazole, and of other 2-chloroethyl compounds
JP2008510784A (ja) プリン及びピリミジンｃｄｋ阻害剤、並びに自己免疫疾患の治療のためのそれらの使用
Ramli et al. A Mechanistic Review on Toxicity Effects of Methamphetamine
US2779707A (en) Soluble cortisone and hydroxycortisone compositions
US5149688A (en) Methods, compounds, and compositions for immunosuppression
CN113197905B (zh) 三萜类化合物在制备神经母细胞瘤治疗药物中的应用
NL2025730B1 (en) Compounds for treatment of sepsis
EP3048886B1 (en) 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use
IL40050A (en) Compositions for treating microbial infections containing piperidine derivatives
AU2017272891B2 (en) Combination therapy comprising a polyunsaturated ketone and a corticosteroid